The targeted protein degradation field has reached a pivotal moment. In June 2025, Arvinas and Pfizer submitted a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), an estrogen receptor (ER)-targeting PROTAC, with the submission granted priority review status. If approved, vepdegestrant would become the first PROTAC to reach the market, validating a therapeutic modality that has been in development for over two decades.
For researchers who have followed the PROTAC field from its academic origins through preclinical proof-of-concept and into clinical trials, this submission represents a watershed. The technology that Craig Crews and colleagues first described in 2001 – using bifunctional molecules to hijack the cell’s protein disposal machinery – is on the verge of delivering its first approved medicine.
How Vepdegestrant Works
Like all PROTACs, vepdegestrant is a bifunctional molecule with two business ends connected by a chemical linker. One end binds to the target protein – in this case, the estrogen receptor. The other end recruits an E3 ubiquitin ligase, the cellular enzyme that tags proteins for destruction by the proteasome. By bringing the ER and the E3 ligase into proximity, vepdegestrant triggers ubiquitination and subsequent degradation of the receptor.
This degradation mechanism offers a fundamental advantage over traditional ER antagonists like fulvestrant and tamoxifen. Conventional antagonists block the receptor’s activity but leave the protein intact. The receptor can still serve as a scaffold for other signaling interactions, and mutations in the ligand-binding domain can reduce drug binding, leading to resistance. By eliminating the entire protein, vepdegestrant removes both the canonical signaling activity and the scaffolding functions, potentially overcoming resistance mechanisms that limit current therapies.
The clinical data from the Phase 3 VERITAC trial demonstrated that vepdegestrant improves survival outcomes compared with fulvestrant in patients with ER-positive, HER2-negative metastatic breast cancer harboring ER mutations. These ESR1 mutations, which arise during treatment with aromatase inhibitors and other endocrine therapies, are a major driver of resistance to standard-of-care treatments. Vepdegestrant’s ability to degrade mutant ER is a key differentiator.
The PROTAC Pipeline Beyond Vepdegestrant
Vepdegestrant is the furthest advanced, but it’s not alone. Three PROTACs have now reached Phase 3 clinical trials. Bristol Myers Squibb’s BMS-986365 targets the androgen receptor (AR) in prostate cancer, and BeiGene’s BGB-16673 targets BTK in B-cell malignancies. Each addresses a disease setting where target protein degradation may offer advantages over conventional inhibition.
In earlier-stage development, the oral STAT6 degrader KT-621 from Kymera Therapeutics has shown remarkable results in atopic dermatitis, achieving 96% STAT6 degradation in blood and 94% in skin tissue. This program is noteworthy because it demonstrates that PROTACs can work outside of oncology, potentially opening therapeutic areas where traditional small molecule inhibitors have struggled.
What This Means for Degradation Research
The clinical validation of the PROTAC mechanism has energized the broader targeted protein degradation research community. Academic labs and biotech companies are exploring PROTACs against an expanding list of targets, including transcription factors, structural proteins, and other historically “undruggable” proteins.
For researchers working on PROTAC design and optimization, access to high-quality building blocks is essential. The three key components of any PROTAC – the target ligand (warhead), the E3 ligase recruiting element (anchor), and the linker connecting them – each require optimization. Immunomart carries several compounds relevant to ER-targeting degradation research, including ARV-471 (vepdegestrant itself as a research reference standard), PROTAC ER Degrader-15, ER degrader 10, and ER-alpha degrader 12.
For the E3 ligase side, the CRBN-recruiting element thalidomide and its derivatives remain the most commonly used anchors. Compounds like Ethanolamine-Thalidomide-4-OH provide building blocks for PROTAC synthesis. The ER ligand-7 offers an alternative warhead for ER-targeting degrader design.
Technical Considerations in PROTAC Research
The success of vepdegestrant should not obscure the considerable technical challenges in PROTAC development. These molecules are larger than typical small molecules (vepdegestrant has a molecular weight around 730 Da), which creates challenges for oral bioavailability, cell permeability, and tissue distribution. The fact that vepdegestrant achieves oral bioavailability sufficient for clinical efficacy represents a significant medicinal chemistry achievement.
Linker design remains one of the most empirical aspects of PROTAC optimization. The length, flexibility, and chemical composition of the linker influence the ternary complex geometry – the three-dimensional arrangement of target protein, PROTAC, and E3 ligase – which in turn determines degradation efficiency. Small changes in linker structure can dramatically affect potency, selectivity, and pharmacokinetic properties.
Researchers investigating these structure-activity relationships need panels of related PROTAC compounds to systematically explore the design space. Reference standards and building blocks from suppliers like Immunomart support this iterative process, enabling labs to synthesize and test PROTAC variants without building every component from scratch.
Beyond PROTACs: The Degradation Ecosystem
The targeted protein degradation field has expanded beyond the classical PROTAC architecture. Molecular glues, which stabilize interactions between a target protein and an E3 ligase without the traditional bifunctional structure, have produced approved drugs (lenalidomide, pomalidomide) and are being designed with increasing rationality. Polymer-based targeting chimeras (PolyTACs) are being developed to degrade membrane proteins and secreted proteins that conventional PROTACs cannot reach.
For the BET bromodomain target family, which has been extensively studied in the degradation context, compounds like BRD4 degrader-5, (+)-JQ-1, and I-BET151 provide a toolkit spanning from traditional inhibition to targeted degradation, allowing researchers to compare pharmacological outcomes between the two modalities.
Looking Ahead
The FDA review of vepdegestrant will be closely watched by the entire drug discovery community. A positive outcome would validate the PROTAC mechanism at the highest regulatory level and likely accelerate investment in degradation-based approaches across therapeutic areas. For researchers working in this space, the coming months represent an exciting period where years of fundamental science may translate into a new class of approved medicines.
Research Use Only Disclaimer: All small molecule inhibitors and research compounds mentioned in this article are intended for laboratory research use only (RUO). They are not approved for human or veterinary use, not intended for diagnostic or therapeutic purposes, and must not be used as drugs, food additives, or household chemicals. Always follow your institution’s safety protocols when handling research compounds.
